Search

Your search keyword '"Huang, Jingcao"' showing total 149 results
Start Over Author "Huang, Jingcao" Search Limiters Peer Reviewed
149 results on '"Huang, Jingcao"'

4. Decreased RNA‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide

Author

Lin, Zhimei, primary, Zhang, Yue, additional, Liu, Xiang, additional, Luo, Hongmei, additional, Li, Qian, additional, Gao, Qianwen, additional, Wang, Xin, additional, Wen, Jingjing, additional, Li, Linfeng, additional, Feng, Yu, additional, Wang, Fangfang, additional, Huang, Jingcao, additional, Zhai, Xinyu, additional, Zhang, Li, additional, Niu, Ting, additional, and Zheng, Yuhuan, additional

Published
2024
Full Text
View/download PDF

6. Single‐cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.

Author

Wang, Xin, Feng, Yu, Wang, Fangfang, Lin, Zhimei, Huang, Jingcao, Li, Qian, Luo, Hongmei, Liu, Xiang, Zhai, Xinyu, Gao, Qianwen, Li, Linfeng, Zhang, Yue, Wen, Jingjing, Zhang, Li, Niu, Ting, and Zheng, Yuhuan

Abstract

Aggrephagy, a type of autophagy, degrades the aggregation of misfolded protein in cells. However, the role of aggrephagy in multiple myeloma (MM) has not been fully demonstrated. In this study, we first investigated the correlation between aggrephagy signaling, MM immune microenvironment composition and disease prognosis. Single‐cell RNA‐seq data, including the expression profiles of 12,187 single cells from seven MM bone marrow (BM) and seven healthy BM samples, were analyzed by non‐negative matrix factorization for 44 aggrephagy‐related genes. Bulk RNA‐seq cohorts from the Gene Expression Omnibus database were used to evaluate the prognostic value of aggrephagy‐related immune cell subtypes and predict immune checkpoint blockade immunotherapeutic response in MM. Compared with healthy BM, MM BM exhibited different patterns of aggrephagy‐related gene expression. In MM BM, macrophages, CD8+ T cells, B cells and natural killer cells could be grouped into four to nine aggrephagy‐related subclusters. The signature of aggrephagy signaling molecule expression in the immune cells correlates with the patient's prognosis. Our investigation provides a novel view of aggrephagy signaling in MM tumor microenvironment cells, which might be a prognostic indicator and potential target for MM treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. ALCAM-EGFR interaction regulates myelomagenesis

Author

Luo, Hongmei, Zhang, Dan, Wang, Fangfang, Wang, Qiang, Wu, Yu, Gou, Maling, Hu, Yiguo, Zhang, Wenyan, Huang, Jingcao, Gong, Yuping, Pan, Ling, Li, Tianshu, Zhao, Pan, Zhang, Danfeng, Qu, Ying, Liu, Zhigang, Jiang, Tao, Dai, Yang, Guo, Tingting, Zhu, Jiang, Ye, Lingqun, Zhang, Li, Liu, Weiping, Yi, Qing, and Zheng, Yuhuan

Published
2021
Full Text
View/download PDF

11. A Ferroptosis-Related Prognostic Model of Mantle Cell Lymphoma

Author

Gao, Qianwen, primary, Wang, Xin, additional, Zhang, Yue, additional, Wen, Jingjing, additional, Wang, Fangfang, additional, Lin, Zhimei, additional, Feng, Yu, additional, Huang, Jingcao, additional, Li, Qian, additional, Luo, Hongmei, additional, Liu, Xiang, additional, Zhai, Xinyu, additional, Li, Linfeng, additional, Zhang, Li, additional, Niu, Ting, additional, Xu, Caigang, additional, and zheng, yuhuan, additional

Published
2023
Full Text
View/download PDF

18. Correlation of Aggrephagy Signaling and Multiple Myeloma Immune Microenvironment Composition

Author

Wang, Xin, primary, Feng, Yu, additional, Wang, Fangfang, additional, Lin, Zhimei, additional, Huang, Jingcao, additional, Li, Qian, additional, Luo, Hongmei, additional, Liu, Xiang, additional, Zhai, Xinyu, additional, Gao, Qianwen, additional, Li, Linfeng, additional, Zhang, Yue, additional, Wen, Jingjing, additional, Zhang, Li, additional, Niu, Ting, additional, and Zheng, Yuhuan, additional

Published
2023
Full Text
View/download PDF

19. Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity

Author

Lin, Zhimei, primary, Chu, Bingyang, additional, Qu, Ying, additional, Wei, Xue, additional, Huang, Jingcao, additional, Wang, Fangfang, additional, Feng, Yu, additional, Wang, Xin, additional, Luo, Hongmei, additional, Zhai, Xinyu, additional, Xu, Juan, additional, Liu, Xiang, additional, Zhang, Li, additional, Chen, Fengjiao, additional, Wu, Yu, additional, and Zheng, Yuhuan, additional

Published
2022
Full Text
View/download PDF

23. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

Author

Yang, Yan, primary, Gao, Yuhan, additional, Huang, Jingcao, additional, Yang, Zhuang, additional, Luo, Hongmei, additional, Wang, Fangfang, additional, Xu, Juan, additional, Cui, Yushan, additional, Ding, Hong, additional, Lin, Zhimei, additional, Zhai, Xinyu, additional, Qu, Ying, additional, Zhang, Li, additional, Liu, Ting, additional, Ye, Lingqun, additional, Niu, Ting, additional, and Zheng, Yuhuan, additional

Published
2022
Full Text
View/download PDF

31. Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma

Author

Xu, Juan, primary, Yu, Nanhui, additional, Zhao, Pan, additional, Wang, Fangfang, additional, Huang, Jingcao, additional, Cui, Yushan, additional, Ding, Hong, additional, Yang, Yan, additional, Gao, Yuhan, additional, Pan, Ling, additional, Chang, Hong, additional, Wu, Yu, additional, Xiang, Bing, additional, Gong, Yuping, additional, Shuai, Xiao, additional, Hou, Li, additional, Xie, Liping, additional, Niu, Ting, additional, Liu, Ting, additional, Zhang, Li, additional, Liu, Weiping, additional, Zhang, Wenyan, additional, Qu, Ying, additional, Lin, Wei, additional, Zhu, Yimin, additional, Zhao, Sha, additional, and Zheng, Yuhuan, additional

Published
2021
Full Text
View/download PDF

32. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway

Author

Wang, Fangfang, primary, Huang, Jingcao, additional, Guo, Tingting, additional, Zheng, Yuhuan, additional, Zhang, Li, additional, Zhang, Dan, additional, Wang, Fujue, additional, Naren, Duolan, additional, Cui, Yushan, additional, Liu, Xiaoyan, additional, Qu, Ying, additional, Luo, Hongmei, additional, Yang, Yan, additional, Wei, Haichen, additional, and Guo, Yong, additional

Published
2021
Full Text
View/download PDF

34. Estrogen‐Responsive Gene MAST4 Regulates Myeloma Bone Disease.

Author

Cui, Yushan, Wang, Fangfang, Zhang, Danfeng, Huang, Jingcao, Yang, Yan, Xu, Juan, Gao, Yuhan, Ding, Hong, Qu, Ying, Zhang, Wenyan, Liu, Weiping, Pan, Ling, Zhang, Li, Liu, Zhigang, Niu, Ting, Liu, Ting, and Zheng, Yuhuan

Abstract

Our previous data showed that young female multiple myeloma (MM) patients had a low frequency of osteolytic lesions. Based on this clinical observation, we found that estrogen cell signaling played a regulatory role in MM bone disease (MMBD), and the estrogen‐responsive gene microtubule‐associated serine/threonine kinase family member 4 (MAST4) was a critical factor. The presence of estrogen in cell cultures promoted MAST4 expression in MM cells, while knocking down estrogen receptor 1 (ESR1) inhibited MAST4 expression. Chromatin immunoprecipitation assay suggested a binding site of ESR1 on the MAST4 promoter. Bisphosphonates, such as zoledronic acid (ZOL), which was widely used in MMBD control, could stimulate MAST4 expression in MM cells by promoting ESR1 expression. MAST4 interacted with phosphatase and tensin homolog (PTEN), therefore regulating the PI3K‐Akt‐mTOR pathway and the expression of downstream cytokines, such as CCL2/3/4. MAST4 knockdown (MAST4‐KD) or ESR1 knockdown (ESR1‐KD) MM cells had repressed PTEN activity, elevated PI3K‐Akt‐mTOR activity, and increased CCL2/3/4 expressions. Coculture of MAST4‐KD or ESR1‐KD MM cells with pre‐osteoclasts (pre‐OCs) stimulated OC formation in vitro, whereas neutralizing antibodies of CCL2/3/4 attenuated such stimulation. In mouse models, mice inoculated with MAST4‐KD or ESR1‐KD MM cells had severer MMBD than control knockdown (CTR‐KD). The correlations between MAST4 and ESR1 expressions in MMBD, as well as related cell signaling pathways, were confirmed in analyses using gene expression profiles (GEPs) of patients' MM cells. The negative correlation of MAST4 expression and occurrence of MMBD was further validated by patients' immunohistochemical tissue array. Overall, our data suggested that estrogen cell signaling negatively regulated MMBD through MAST4. © 2022 American Society for Bone and Mineral Research (ASBMR). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease

Author

Cui, Yushan, primary, Wang, Fangfang, additional, Zhang, Danfeng, additional, Huang, Jingcao, additional, Yang, Yan, additional, Xu, Juan, additional, Gao, Yuhan, additional, Ding, Hong, additional, Qu, Ying, additional, Zhang, Wenyan, additional, Liu, Weiping, additional, Pan, Ling, additional, Zhang, Li, additional, Liu, Zhigang, additional, Niu, Ting, additional, Liu, Ting, additional, and Zheng, Yuhuan, additional

Published
2020
Full Text
View/download PDF

44. Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia

Author

Luo, Hongmei, primary, Qin, Yu, additional, Reu, Frederic, additional, Ye, Sujuan, additional, Dai, Yang, additional, Huang, Jingcao, additional, Wang, Fangfang, additional, Zhang, Dan, additional, Pan, Ling, additional, Zhu, Huanling, additional, Wu, Yu, additional, Niu, Ting, additional, Xiao, Zhijian, additional, Zheng, Yuhuan, additional, and Liu, Ting, additional

Published
2016
Full Text
View/download PDF

45. MicroRNA regulation and therapeutic targeting of survivin in cancer

Author

Huang, Jingcao, Lyu, Hui, Wang, Jianxiang, and Liu, Bolin

Subjects
Review Article, neoplasms
Abstract

Survivin, the smallest member of IAP (inhibitor of apoptosis) family, is a dual functional protein acting as a critical apoptosis inhibitor and key cell cycle regulator. Survivin is usually expressed in embryonic tissues during development and undetectable in most terminally differentiated tissues. Numerous studies demonstrate that survivin is selectively upregulated in almost all types of human malignancies and its overexpression positively correlates with poor prognosis, tumor recurrence, and therapeutic resistance. This differential expression of survivin in tumors and normal tissues draws a great interest to develop survivin-targeted therapy for cancer treatment. Nonetheless, the molecular mechanisms controlling survivin expression in malignant tumor cells have not been fully understood. While aberrant activation of receptor tyrosine kinases (RTKs) and the downstream signaling, such as PI-3K/Akt, MEK/MAPK, mTOR, and STAT pathways, have frequently been shown to upregulate survivin, recent data suggest that a class of noncoding RNAs, microRNAs (miRNAs) also play an important role in survivin dysregulation in human cancers. Here, we focus on survivin expression-regulated by specific miRNAs binding to the 3'-UTR of survivin mRNA, and summarize the latest advances on survivin-targeted therapy in clinical trials and the therapeutic potential of survivin-targeting miRNAs in cancer.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results